U.S. CAR-T Cell Therapy Market Overview
According to fortune business insights, the U.S. CAR-T cell therapy market size was worth USD 3.00 billion in 2023 and is projected to grow at a CAGR of 18.7% during the forecast period. Chimeric antigen receptor (CAR) T-cell therapy is a novel approach that modifies a patient's T-cells to target and destroy cancer cells. The market growth is driven by the significant rise in the incidence of cancers like leukemia and multiple myeloma, with over 1.2 million Americans developing cancer each year.
Growing awareness and promising results are prompting key players to increase investment in R&D. The market was minimally impacted by the COVID-19 pandemic, as reduced clinical trials were offset by some patients continuing to undergo treatment.
Major Players Profiled in the Market Report:
- Bristol-Myers Squibb Company (U.S.)
- Ferring B.V. (Switzerland)
- Johnson & Johnson Services, Inc. (U.S.)
- Novartis AG (Switzerland)
- Spark Therapeutics, Inc. (U.S.)
- Enzyvant Therapeutics GmbH (U.S.)
- bluebird bio, Inc. (U.S.)
- Gilead Sciences, Inc. (U.S.)
- CARsgen Therapeutics Holdings Limited (China)
Latest Trends
Growing Research and Development Activities for Cell-Based Therapies
The rising prevalence of cancer is fueling demand for more effective treatments, leading to increased investment in R&D for cell-based therapies. Scientific advancements are focused on overcoming existing challenges and introducing new technologies. A 2022 report indicated that there were 750 active CAR-T therapies in development globally, with 375 in clinical phases, highlighting a robust pipeline that is anticipated to drive market growth.
Drivers & Restraints
Increasing Prevalence of Cancer among Population to Spur Market Growth
The growing prevalence of various cancers is a primary driver for the market, stimulating technological advancements and leading to more product approvals. Innovations are also focused on improving efficiency; for example, a clinical trial for a "FasT CAR-T" technology successfully reduced the T-cell manufacturing time to just 24 hours. Regulatory support, such as the FDA's March 2022 approval of Carvykti for adults with multiple myeloma, continues to boost the market.
High Cost Associated with CAR-T Cell Therapy Might Hinder the Market Growth
Despite its increasing adoption, the high cost of CAR-T cell therapy is a significant restraint. For example, the list price for a one-time infusion of cilta-cel therapy was reported to be USD 465,000. Additional constraints, such as the limited availability and time required for T-cell manufacturing, may also hamper market growth.
For detailed market insights: https://www.fortunebusinessinsights.com/u-s-car-t-cell-therapy-market-109015
Segments
Yescarta Segment to Dominate by Drug
Based on drug, the market is segmented into yescarta, tecartus, carvykti, abecma, breyanzi, kymriah, and others. The yescarta segment held the largest share in 2022, owing to benefits such as a longer survival rate and a reduction in the risk of death. For instance, the Phase-3 ZUMA 7 clinical study demonstrated that Yescarta resulted in a 27.4% reduction in the risk of death.
Multiple Myeloma Segment to Exhibit Highest Growth by Indication
By indication, the market includes acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma (NHL), and multiple myeloma. The multiple myeloma segment is projected to grow at the highest CAGR. This is due to its increasing prevalence and the rising number of therapy approvals for this indication.
Hospitals Segment to Lead by End User
Based on end user, the market is divided into hospitals and oncology treatment centers. Hospitals held the largest share in 2022. This is attributed to rising inpatient and outpatient admissions, a growing rate of diagnosis, and the large number of hospital facilities in the U.S. (approximately 6,093 as of October 2022).
Competitive Landscape
Strong R&D and Product Launches Define the Market
The market includes both established and emerging companies. Leading players such as Novartis AG, Ferring B.V., and Johnson & Johnson Services, Inc. hold a significant share due to strong R&D activities and an increasing number of product launches. For instance, in February 2022, Janssen (a Johnson & Johnson company) received FDA approval for CARVYKTI to treat multiple myeloma. Other companies, including Gilead Sciences, Inc. and Bristol-Myers Squibb Company, are focusing on strategic collaborations and acquisitions to enhance their market position.
Key Industry Development
- May 2023: Janssen Biotech collaborated with Cellular Biomedicine Group (CBMG) to develop next-generation CAR-T cell therapies for B-cell malignancies.
- June 2022: The U.S. FDA approved Bristol Myers Squibb's CAR T-cell therapy, Breyanzi, for patients with relapsed or refractory large B-cell lymphoma.
- March 2021: The U.S. FDA approved Abecma, developed by Bristol Myers Squibb and bluebird bio, for patients with relapsed or refractory multiple myeloma.
Report Coverage
The report provides a detailed analysis of the market, including:
- An overview of technological advancements and cancer prevalence in the U.S.
- Details on the reimbursement and regulatory scenario.
- Key industry developments such as mergers, partnerships, and acquisitions.
- The impact of COVID-19 on the market.
- A comparative analysis of the product portfolios of key companies.
Uncover Japan’s Market Trends - Explore the Latest U.S. CAR-T Cell Therapy Market Insights
Comments